Remove Drugs Remove Genetic Analysis Remove RNA
article thumbnail

Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer

Delveinsight

Beam adds to drug delivery stable with USD 120 Million GuideTx buy. Beam Therapeutics has taken over a startup whose technology could proffer the biotech’s genetic medicines to more tissues in the body, widening the potential to approach more diseases. GRAIL and Quest collaborate for the cancer blood test.

DNA 52
article thumbnail

Top 10 Biotech Trends for 2025

XTalks

From leveraging artificial intelligence (AI) to streamline diagnostics and treatments to exploring the untapped potential of RNA-based therapeutics, biotechnology is shaping the future of healthcare and beyond. As of January 31, 2024, approximately 131 unique RNA-based therapies are in clinical development across various therapeutic areas.